Overcoming Bottlenecks in Drug Discovery By Dr Trevor Perrior Developing a new drug is an expensive and time-consuming process. The best current estimate puts the cost of developing a single new drug at close to $1 billion. After a drug candidate has entered… Read More
Biomarkers Make Their Mark on Current Research and Drug Development Trends By Stephane Parent and Dr Gregory Cosentino Biomarkers continue to become increasingly relevant in research and healthcare applications, as evidenced by the global market for products involved in their identification, validation, and use estimated at $8.3 billion… Read More
Enterprise ELNs as a Foundation for Preclinical Drug Development By Simon Beaulah, Dr Paul Denny- Gouldson and Dr Scott Weiss To have real business impact within preclinical drug development, Enterprise ELNs (Electronic Laboratory Notebooks) must provide a secure, scalable and searchable data management backbone across all disciplines focused… Read More
Personalised Medicine Market and Regulatory Landscape By Dr Enal Razvi and Dr Patricia Hurley Over the past several years, there has been continuing interest in the deployment of personalised medicine via the development of companion diagnostics/therapeutics. The leading edge of this discipline is… Read More
Tracking HTS Assay Development Time: Opportunity for improving drug discovery By Dr Jennifer Hartigan, Cindy Liu and William Downey High throughput screening (HTS) assays are developed more quickly now due to advances in technology, improved liquid handling and sensitive detection, as well as increased communication between scientists in… Read More
Fluorescence Lifetime: Finally picking up momentum! By Dr John Comley Fluorescence lifetime (FLT) largely failed to make a significant inroad as a screening technology when it was first introduced nearly a decade ago, despite the fact that intrinsically it has many benefits, particularly in dealing with assay… Read More
Overview of Companion Diagnostics in the Pharmaceutical Industry Part 2: Business models. By Dr Stephen Naylor and Toby Cole There is an emerging consensus that the development of Companion Diagnostics appears to offer a set of tools to address many… Read More
Towards Unbiased Biomarker Discovery Dr Jens Hoefkens High-throughput molecular profiling technologies are routinely applied for biomarker discovery to make the drug discovery process more efficient and enable personalised medicine. The ability to find novel biomarkers rests on large-scale data generation and unbiased data analysis. Over the… Read More
By Dr Mikael Kubista Quantitative real-time PCR is becoming mature technology for the quantification of nucleic acids. It is spreading wide outside its original use in the research laboratories, becoming preferred technology for a range of applications, many that require specialised so lutions and adaptations. Integration with pre-analytical steps and… Read More
Design Of Experiments: Useful statistical tool in assay development or vendor disconnect By Dr John Comley The use of design of experiments (DOE) in assay development (AD) has the potential to speed up assay optimisation (ie reduce assay development bottlenecks) and to facilitate a more thorough evaluation of… Read More
Free Online Resources Enabling Crowd-Sourced Drug Discovery By Dr Antony J. Williams, Valery Tkachenko, Dr Chris Lipinski, Professor Alexander Tropsha and Dr Sean Ekins The availability of freely accessible online resources to enable and support drug discovery has blossomed in recent years. The PubChem platform is now accompanied… Read More
Current and Emerging Trends in Cell-Based Assays – Roundtable In 2009 Drug Discovery World hosted a collegial-style roundtable discussion on the present and emerging developments in this exciting and now, fundamental area of drug discovery. The participants are recognised to be thought leaders… Read More
Innovations In Drug Discovery Technology By Dr Al Kolb Technology has been a major driver of advances in drug discovery. Automation, nanofluidics, imaging, software and assay technologies have played a major role in getting better data, faster. Is drug discovery at such an advanced… Read More
Custom Carbon-14 Radiolabelling: Investing to meet new challenges By Dave Roberts One consequence of an increasing demand from regulators for robust quantitative data on the behaviour of new drugs in man and for information on the fate of pharmaceuticals in the environment, has been an increase in demand… Read More
Maximising the impact of technologies on drug discovery through portfolio management By Charles S. Dormer, Dr Mark Beggs, Dr Lynn Brennan and Roanna London The opportunities to invest in new technologies in drug discovery are broad and extensive. Knowing where to place your investment and ensuring return… Read More
Multiplexing for biological relevance in high throughput screening By William P. Downey, Dr Jennifer Hartigan and Cindy Liu The multiplexed assay is a technique used increasingly in high throughput screening (HTS) labs to study the complex environment of a target, according to HighTech Business Decisions’ (HTBD) industry… Read More
